In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Impact of preadmission beta blockers and cardiac dysfunction on the incidence of cerebral vasospasm and mortality in aneurysmal subarachnoid hemorrhage

    Final Number:
    106

    Authors:
    Nohra Chalouhi MD; Cory Donovan Bovenzi; Eliza Claire Anderson; Guilherme Barros; Adam Reese; Stavropoula I. Tjoumakaris MD; Pascal Jabbour MD; Robert H. Rosenwasser MD, FACS, FAHA; Fred Rincon

    Study Design:
    Other

    Subject Category:
    Aneurysm/Subarachnoid Hemorrhage

    Meeting: AANS/CNS Cerebrovascular Section 2015 Annual Meeting

    Introduction: Vasospasm is a frequent complication of aneurysmal subarachnoid hemorrhage (SAH), with a significant impact on disease course. The purpose of the present study was to assess the impact of preadmission beta-blockers and cardiac dysfunction on the incidence of vasospasm and mortality following SAH.

    Methods: The study population included 210 consecutive patients treated for aneurysmal SAH at Jefferson Hospital for Neuroscience. The occurrence of vasospasm was assessed by serial transcranial Doppler and/or the need for endovascular intervention for medically refractory vasospasm.

    Results: The proportion of patients with any mean flow velocity >120 cm/sec was 22% in patients taking prehospital beta-blockers versus 59% in those not taking prehospital beta-blockers (p=0.003). In multivariate analysis, preadmission beta-blockers (OR 4.5; p=0.002) and lower Hunt and Hess grades (OR 3.9; p<0.001) negatively predicted vasospasm. Fourteen patients required an endovascular intervention for medically refractory vasospasm; none were taking prehospital beta-blockers. In multivariate analysis, decreasing ejection fraction (OR 3.9; p=0.05) independently predicted medically refractory vasospasm. The rate of in-hospital mortality was 47.4% in patients with left ventricular motion wall abnormality versus 14.8% in those without (p<0.001). In multivariate analysis, left ventricle motion wall abnormality (OR 2.7; p=0.002) and decreasing ejection fraction (OR 1.1; p=0.05) were independent predictors of in-hospital mortality.

    Conclusions: The results of this study suggest that preadmission beta-blockers are associated with decreased incidence of cerebral vasospasm in patients with aneurysmal SAH. Beta-blockers may be a promising therapeutic avenue for vasospasm and may need to be continued/started in patients with SAH. Left ventricular dysfunction was associated with medically refractory vasospasm and in-hospital mortality.

    Patient Care: Beta blockers may be an unrecognized treatment for cerebral vasospasm. Also, cardiac dysfunction needs to be recognized as a major determinant of outcome and acted upon in the setting of SAH

    Learning Objectives: 1)To describe the relationship between cardiac dysfunction and outcome in the setting of SAH 2) To discuss the relationship between preadmission betablockers and outcomes in SAH

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy